REPL
Price
$5.40
Change
+$0.02 (+0.37%)
Updated
Aug 29 closing price
Capitalization
421.5M
78 days until earnings call
SNDX
Price
$16.33
Change
+$0.01 (+0.06%)
Updated
Aug 29 closing price
Capitalization
1.41B
71 days until earnings call
Interact to see
Advertisement

REPL vs SNDX

Header iconREPL vs SNDX Comparison
Open Charts REPL vs SNDXBanner chart's image
Replimune Group
Price$5.40
Change+$0.02 (+0.37%)
Volume$2.26M
Capitalization421.5M
Syndax Pharmaceuticals
Price$16.33
Change+$0.01 (+0.06%)
Volume$1.61M
Capitalization1.41B
REPL vs SNDX Comparison Chart in %
Loading...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REPL vs. SNDX commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a Hold and SNDX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (REPL: $5.40 vs. SNDX: $16.33)
Brand notoriety: REPL and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REPL: 20% vs. SNDX: 68%
Market capitalization -- REPL: $421.5M vs. SNDX: $1.41B
REPL [@Biotechnology] is valued at $421.5M. SNDX’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REPL’s FA Score shows that 1 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • REPL’s FA Score: 1 green, 4 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than REPL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REPL’s TA Score shows that 3 TA indicator(s) are bullish while SNDX’s TA Score has 5 bullish TA indicator(s).

  • REPL’s TA Score: 3 bullish, 3 bearish.
  • SNDX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SNDX is a better buy in the short-term than REPL.

Price Growth

REPL (@Biotechnology) experienced а -4.76% price change this week, while SNDX (@Biotechnology) price change was +0.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.59%, and the average quarterly price growth was +30.71%.

Reported Earning Dates

REPL is expected to report earnings on Nov 18, 2025.

SNDX is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.41B) has a higher market cap than REPL($422M). SNDX YTD gains are higher at: 23.525 vs. REPL (-55.409). REPL has higher annual earnings (EBITDA): -268.18M vs. SNDX (-314.25M). SNDX has more cash in the bank: 469M vs. REPL (403M). SNDX has less debt than REPL: SNDX (1.68M) vs REPL (76.3M). SNDX has higher revenues than REPL: SNDX (77.9M) vs REPL (0).
REPLSNDXREPL / SNDX
Capitalization422M1.41B30%
EBITDA-268.18M-314.25M85%
Gain YTD-55.40923.525-236%
P/E RatioN/AN/A-
Revenue077.9M-
Total Cash403M469M86%
Total Debt76.3M1.68M4,555%
FUNDAMENTALS RATINGS
REPL vs SNDX: Fundamental Ratings
REPL
SNDX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10090
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
9538
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (17) in the Biotechnology industry is significantly better than the same rating for SNDX (84). This means that REPL’s stock grew significantly faster than SNDX’s over the last 12 months.

SNDX's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as REPL (100). This means that SNDX’s stock grew similarly to REPL’s over the last 12 months.

REPL's SMR Rating (98) in the Biotechnology industry is in the same range as SNDX (99). This means that REPL’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for REPL (95). This means that SNDX’s stock grew somewhat faster than REPL’s over the last 12 months.

SNDX's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for REPL (100). This means that SNDX’s stock grew significantly faster than REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REPLSNDX
RSI
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 5 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 25 days ago
78%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
84%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CFVLX34.39N/A
N/A
Commerce Value
GQLIX34.57-0.16
-0.46%
GMO Quality I
DGLYX21.56-0.11
-0.51%
BNY Mellon Global Stock - Y
BINSX15.14-0.10
-0.66%
Baillie Gifford International Alpha I
PQDMX16.26-0.12
-0.73%
PGIM Quant Solutions Intl Dev Mkts IdxR6

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IMNN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IMNN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
+0.37%
IMNN - REPL
56%
Loosely correlated
-1.66%
SNDX - REPL
49%
Loosely correlated
+0.06%
KYMR - REPL
46%
Loosely correlated
-1.32%
ERAS - REPL
44%
Loosely correlated
N/A
BEAM - REPL
43%
Loosely correlated
-2.91%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with REPL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
+0.06%
REPL - SNDX
50%
Loosely correlated
+0.37%
CGON - SNDX
49%
Loosely correlated
+0.39%
ETNB - SNDX
47%
Loosely correlated
-4.14%
IDYA - SNDX
47%
Loosely correlated
-1.52%
RNA - SNDX
47%
Loosely correlated
-4.12%
More